Risk factors and secondary prevention in women with heart disease: The heart and estrogen/progestin replacement study

Annals of Internal Medicine

Volumn 138, Issue 2, 2003, Pages 81-89

  Vittinghoff, Eric ^a   Shlipak, Michael G ^b   Varosy, Paul D ^b   Furberg, Curt D ^b   Ireland, Christine C ^b   Khan, Steven S ^b   Blumenthal, Roger ^b   Barrett Connor, Elizabeth ^b   Hulley, Stephen ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0037458219     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-2-200301210-00007     Document Type: Article

References (48)

1. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation. 1997;96:2468-82. [PMID: 9337227]
2. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation. 1998;97:1876-87. [PMID: 9603549]
3. Denke MA. Primary prevention of coronary heart disease in postmenopausal women. Am J Med. 1999;107:48S-50S. [PMID: 10484243]
4. Willett WC, Green A, Stampfer MJ, Speizer FE, Colditz GA, Rosner B, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317:1303-9. [PMID: 3683458]
5. Kannel WB, Higgins M. Smoking and hypertension as predictors of cardiovascular risk in population studies. J Hypertens Suppl. 1990;8:S3-8. [PMID: 2286855]
6. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol. 1992;2:161-76. [PMID: 1342259]
7. Barrett-Connor E. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation. 1997;95:252-64. [PMID: 8994444]
8. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. [PMID: 9603539]
9. Manson JE. Prevention of Myocardial Infarction. New York: Oxford Univ Pr; 1996.
10. Moss AJ, DeCamilla JJ, Davis HP, Bayer L. Clinical significance of ventricular ectopic beats in the early posthospital phase of myocardial infarction. Am J Cardiol. 1977;39:635-40. [PMID: 67792]
11. Henning H, Gilpin EA, Covell JW, Swan EA, O'Rourke RA, Ross J Jr. Prognosis after acute myocardial infarction: a multivariate analysis of mortality and survival. Circulation. 1979;59:1124-36. [PMID: 436204]
12. Epstein SE, Palmeri ST, Patterson RE. Current concepts: evaluation of patients after acute myocardial infarction: indications for cardiac catheterization and surgical intervention. N Engl J Med. 1982;307:1487-92. [PMID: 6755248]
13. O'Rourke RA. Risk stratification after myocardial infarction. Clinical overview. Circulation. 1991;84:I177-81. [PMID: 1884483]
14. Schlant RC, Forman S, Stamler J, Canner PL. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the coronary drug project. Circulation. 1982;66:401-14. [PMID: 7094247]
15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13. [PMID: 9718051]
16. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19:314-35. [PMID: 9683309]
17. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46. [PMID: 9385294]
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. [PMID: 1244564]
19. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD, et al. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;38:705-11. [PMID: 11527621]
20. Hulley SB, Grady D, Vittinghoff E, Bush T, Furberg C, Herrington D, et al. Hormone replacement therapy for secondary prevention of coronary heart disease [Letter]. JAMA. 1999;281:796-7.
21. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-52. [PMID: 10770146]
22. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. [PMID: 11368702]
23. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23. [PMID: 8501844]
24. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001;134:173-81. [PMID: 11177329]
25. Siegel D, Grady D, Browner WS, Hulley SB. Risk factor modification after myocardial infarction. Ann Intern Med. 1988;109:213-8. [PMID: 3291658]
26. Kronmal RA, Cain KC, Ye Z, Omenn GS. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern Med. 1993;153:1065-73. [PMID: 8481074]
27. Psaty BM, Furberg CD, Kuller LH, Bild DE, Rautaharju PM, Polak JF, et al. Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study. Arch Intern Med. 1999;159:1339-47. [PMID: 10386510]
28. Factors influencing long-term prognosis after recovery from myocardial infarction - three-year findings of the coronary drug project. J Chronic Dis. 1974;27:267-85. [PMID: 4610000]
29. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 1999;33:2092-197. [PMID: 10362225]
30. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13:180-93. [PMID: 2490833]
31. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-36. [PMID: 11304102]
32. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628-37. [PMID: 10807470]
33. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-9. [PMID: 10716471]
34. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation. 1999;100:1016-30. [PMID: 10468535]
35. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. JAMA. 1997;277:1281-6. [PMID: 9109465]
36. Herrington DM, Fong J, Sempos CT, Black DM, Schrott HG, Rautaharju P, et al. Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am Heart J. 1998;136:115-24. [PMID: 9665228]
37. Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit [Editorial]. BMJ. 2000;321:971-2. [PMID: 11039939]
38. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001;357:995-1001. [PMID: 11293642]
39. Allen JK, Blumenthal RS, Margolis S, Young DR. Status of secondary prevention in patients undergoing coronary revascularization. Am J Cardiol. 2001;87:1203-6: A7. [PMID: 11356400]
40. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med. 1999;159:561-7. [PMID: 10090112]
41. Giugliano RP, Camargo CA Jr, Lloyd-Jones DM, Zagrodsky JD, Alexis JD, Eagle KA, et al. Elderly patients receive less aggressive medical and invasive management of unstable angina: potential impact of practice guidelines. Arch Intern Med. 1998;158:1113-20. [PMID: 9605783]
42. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998;339:489-97. [PMID: 9709041]
43. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med. 1998;158:1901-6. [PMID: 9759686]
44. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA. 1998;280:623-9. [PMID: 9718054]
45. Clarke KW, Gray D, Keating NA, Hampton JR. Do women with acute myocardial infarction receive the same treatment as men? BMJ. 1994;309:563-6. [PMID: 7916228]
46. Schwartz LM, Fisher ES, Tosteson NA, Woloshin S, Chang CH, Virnig BA, et al. Treatment and health outcomes of women and men in a cohort with coronary artery disease. Arch Intern Med. 1997;157:1545-51. [PMID: 9236556]
47. Alexander KP, Peterson ED, Granger CB, Casas AC, Van de Werf F, Armstrong PW, et al. Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. J Am Coll Cardiol. 1998;32:2023-30. [PMID: 9857888]
48. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol. 2001;87:819-22. [PMID: 11274933]